Prevail Therapeutics is leading a new era of gene therapy-based treatments with the potential to slow or stop the progression of neurodegenerative diseases, including Gaucher disease and genetic forms of Parkinson's disease.

Founded in partnership with a patient-led research foundation in 2017, Prevail is leveraging recent scientific and technical advancements to accelerate the development of novel treatments for disease communities with urgent unmet needs where limited or no treatments currently exist.

Prevail-Sponsored Clinical Trials

provide
Type 2 Gaucher Disease

PROVIDE is a Phase 1/2 clinical trial assessing the safety and efficacy of PR001, a potentially disease-modifying, single-dose gene therapy for infants diagnosed with Type 2 Gaucher disease.

propel
PD-GBA

PROPEL is a Phase 1/2 clinical trial assessing the safety and efficacy of PR001, a potential disease-modifying, single-dose gene therapy for individuals living with Parkinson's Disease with *GBA1* mutations (PD-GBA).

For additional resources and to learn more about Prevail's research and clinical trials, please visit: https://www.prevailtherapeutics.com/patients/.